Related Experiment Videos
Phase II trial of gallium nitrate in patients with advanced malignant melanoma
Cancer Treatment Reports
|September 1, 1985
Abstract:
A phase II trial of gallium nitrate (250-300 mg/m2/day for 7 consecutive days) was conducted in patients with metastatic melanoma. Therapy was well-tolerated, but only one of 31 evaluable patients experienced a partial regression. Further evaluation of gallium nitrate at this dose and schedule is not warranted in patients with malignant melanoma.